An engineered fusion membrane bubble, preparation method and application thereof
Patent Information
- Application Number
- CN202211684818.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-12-27
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2042-12-27
Smart Images

Figure CN115944752B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to an engineered fusion membrane bubble preparation method and application of the engineered fusion membrane bubble in targeted ultrasound angiography of atherosclerotic plaques. Background Art
[0002] Ultrasound imaging is the most common clinical method for detecting atherosclerosis besides blood tests. It can observe the effect of lesions on blood flow while observing the blockage of plaques in blood vessels. Contrast-enhanced ultrasound can significantly enhance the imaging effect compared to ordinary ultrasound, and clearly display the fine vascular structure of normal and diseased tissues. Since ordinary contrast agents lack specificity or have poor specificity and are easily cleared by the body's immune system, there is an urgent need for a contrast agent with strong specificity and long circulation time in the body to achieve accurate detection of atherosclerotic plaques.
[0003] APOA1 is the main functional protein of high-density lipoprotein (HDL). It can not only bind to the B-type I scavenger receptor SR-BI highly expressed in foam cells, but also form nascent high-density lipoprotein with phospholipids to take up cholesterol, activate phosphatidylcholine cholesterol acyltransferase (LCAT) to convert cholesterol into cholesterol ester and transfer it from peripheral tissues to the liver. Therefore, APOA1 can be used to target atherosclerotic plaques. Literature reports that the membrane components of HepG2 cells contain APOA1. Under nutrient-rich conditions, the level of APOA1 in HepG2 cells maintains a dynamic balance through autophagy clearance and protein synthesis dependent on the mammalian target of rapamycin complex 1 (mTORC1) pathway. Therefore, inhibiting cell autophagy is a potential method to increase the expression level of APOA1. CD47 is a transmembrane glycoprotein widely expressed on the membrane of cancer cells, which has immune escape function and can significantly prolong the circulation time of contrast agents in the body. Summary of the invention
[0004] The main purpose of the present invention is to design an engineered method for preparing fusion membrane bubbles, by adding BAF during the in vitro culture of HepG2 cells to upregulate the expression of APOA1, then extracting the cell membrane and fusing it with artificially synthesized liposomes, and finally filling sulfur hexafluoride gas during the molecular rearrangement of ultrasound at the gas-liquid interface to form fusion membrane bubbles with uniform particle size and stable structure, and applying them in ultrasonic molecular imaging of atherosclerotic plaques.
[0005] To achieve the above objectives, the present invention provides a method for preparing an engineered fusion membrane bubble, comprising the following steps:
[0006] Step S1, treating liver cancer HepG2 cells with BAF, i.e., bafilomycin A1, and then extracting cell membrane using a cell membrane protein extraction kit;
[0007] Step S2, preparing liposomes by rotary evaporation;
[0008] Step S3, preparing a fusion membrane by repeatedly freezing and thawing the cell membrane extracted in step S1 and the liposome prepared in step S2 with liquid nitrogen; and
[0009] Step S4, preparing fusion membrane bubbles from the fusion membrane prepared in step S3 by using an ultrasound-assisted method;
[0010] The liposome is composed of dipalmitoyl phosphatidylcholine, distearate phosphatidylethylamine alcohol-polyethylene glycol 2000, stearic acid and distearate phosphatidyl glycerol, wherein the mass ratio of dipalmitoyl phosphatidylcholine, distearate phosphatidylethylamine alcohol-polyethylene glycol 2000, stearic acid and distearate phosphatidyl glycerol is 10:10:5:4; the mass ratio of the cell membrane suspension protein obtained in step S1 to the liposome obtained in step S2 is 1:50;
[0011] The step S4 comprises the following steps:
[0012] Step S41, taking 1 mL of the fusion membrane solution prepared in step S3 and placing it in a 10 mL vial and placing the vial on ice, opening the gas cylinder to pass sulfur hexafluoride into the vial, and at the same time placing an ultrasonic probe at the gas-liquid interface between sulfur hexafluoride and the fusion membrane solution, controlling the ultrasonic power to 300 W, the frequency to 25 kHz, the on time to 5 seconds, the off time to 5 seconds, and the total time to 1 minute, to obtain a fusion membrane bubble emulsion;
[0013] Step S42, adding 5 mL of the fusion membrane bubble emulsion obtained in step S42 into a 20 mL vial, freezing it in liquid nitrogen for 5-10 minutes, taking it out and freeze-drying it in a -40°C freeze dryer to obtain a freeze-dried powder;
[0014] Step S43, fill the freeze-dried powder bottle obtained in step S43 with 60 mg of sulfur hexafluoride gas, seal the bottle with a rubber stopper, clamp the aluminum cap, and store it in a 4°C refrigerator. When needed, add an equal volume of ultrapure water to reconstitute it, mix it in a water bath with ultrasound at room temperature and 53 kHz, and then inflate it through step S41.
[0015] A further improvement of the present invention is that step S1 comprises the following steps:
[0016] Step S11, the liver cancer cells HepG2 were cultured in a T75 cell culture flask containing RMPI-1640 medium containing 10% serum, washed 2-3 times with phosphate buffered saline (PBS), digested for 2-3 minutes with 4 mL of trypsin solution containing ethylenediaminetetraacetic acid (EDTA), observed under a microscope, and after 80% of the cells fell off, 6 mL of RMPI-1640 medium containing 10% serum was added to terminate the digestion, and then the cells were transferred to a 15 mL centrifuge tube and centrifuged at 900 rpm for 3 minutes. After the supernatant was removed, the cells were resuspended with 1 mL of culture medium, 10 μL of the cell suspension was added to a cell counting plate, and then counted using a cell counter. 4×10 cells were taken for each portion. 6 The cells were added into a 10 cm diameter dish and cultured for 24 hours;
[0017] Step S12, take out the culture medium in the dish of step S11, add PBS to wash 2-3 times, add RMPI-1640 incomplete culture medium containing BAF and incubate in an incubator for 6 hours, after the incubation is completed, remove the culture medium, wash 2-3 times with PBS, add 4 mL PBS, and use a cell scraper to scrape the cells and transfer them to a centrifuge tube;
[0018] Step S13, centrifuge the cells obtained in step S12 at 900 rpm for 3 minutes, remove the supernatant, then add cell membrane protein extraction reagent A to resuspend, mix well and freeze-thaw repeatedly in liquid nitrogen 2-3 times to lyse the cells, centrifuge the lysed cells at 700g and 4°C for 10 minutes to remove the cell nucleus precipitate, collect the supernatant and centrifuge at 14000g and 4°C for 30 minutes to obtain the precipitate, i.e., cell membrane fragments, which contain cell membranes and organelle membranes, resuspend the cell membrane fragments in PBS and sonicate in a water bath for 3-5 minutes to obtain a cell membrane suspension.
[0019] A further improvement of the present invention is that step S2 comprises the following steps:
[0020] The phospholipids described in step S21 and step S2 are dissolved in chloroform and methanol in a volume ratio of 5:1 according to a mass ratio of 10:10:5:4 of dipalmitoylphosphatidylcholine (DPPC), distearate phosphatidylethanolamine-polyethylene glycol 2000 (DSPE-PEG2000), stearic acid and distearate phosphatidylglycerol (DPPG);
[0021] Step S22, rotary evaporate the liposome organic solution prepared in step S21 at 50°C and 100 rpm until a uniform thin film appears at the bottom of the round-bottom flask, remove the round-bottom flask, and vacuum dry it for 15 minutes. After drying, add 2 mL of PBS for every 29 mg of liposomes in the flask, and hydrate it under water bath ultrasound at 50°C, 100 w, 53 kHz for 5-10 minutes to obtain a liposome suspension.
[0022] A further improvement of the present invention is that step S3 comprises the following steps:
[0023] Step S31, mixing the cell membrane suspension obtained in step S1 and the liposome suspension obtained in step S2 at a ratio of 1:50 between the mass of the cell membrane suspension protein and the mass of the liposome. Preferably, the mass ratio of the cell membrane suspension protein to the mass of the liposome is 1:50;
[0024] Step S32, freezing the mixed suspension obtained in step S31 in liquid nitrogen for 2 minutes, and then thawing it in a 37°C water bath under ultrasound, repeating the cycle 3-5 times to obtain a fusion membrane solution.
[0025] In order to achieve the above object of the invention, the present invention also provides an engineered fusion membrane bubble, which is prepared according to the above-mentioned preparation method.
[0026] In order to achieve the above object of the invention, the present invention also provides an engineered fusion membrane bubble, comprising an inert gas inner core and an engineered fusion membrane formed by fusion of cell membrane and liposome, which is coated on the outside of the gas inner core.
[0027] The beneficial effects of the present invention are as follows: the present invention uses BAF to stimulate the in vitro cultured liver cancer cells to express APOA1, then freezes and thaws the cells and then extracts the cell membrane by differential centrifugation, then repeatedly freezes and thaws to promote the full fusion between the phospholipid bilayers to obtain a fusion membrane, and finally fills sulfur hexafluoride gas in the molecular rearrangement process of ultrasonic gas-liquid interface to form fusion membrane bubbles with uniform particle size and stable structure. During the experimental verification process, CD47 and APOA1 on the cell membrane were detected on the surface of the fusion membrane bubbles, and then in the in vitro foam cell model experiment, the fusion membrane bubbles of the present invention specifically target foam cells compared with liposome bubbles, and the potential feasibility of targeting atherosclerotic plaques was verified in vitro. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1 This is a characterization diagram of the APOA1 protein content in the fusion membrane bubble of the present invention: from left to right are the cell membrane of HepG2 cells treated with BAF, the HepG2 cell membrane, and the APOA1 protein content on the fusion membrane bubble.
[0029] Figure 2 Characterization diagram of the cell membrane, liposome, fusion membrane, and fusion membrane bubble of the present invention: Characterization diagram of the particle size and Zeta potential of the cell membrane, fusion membrane, and fusion membrane bubble.
[0030] Figure 3Characterization images of the fusion membrane bubbles of the present invention: from left to right are transmission electron microscopy characterization image of cell membrane, scale ruler = 100 nm; transmission electron microscopy characterization image of liposome, scale ruler = 200 nm; transmission electron microscopy characterization image of fusion membrane, scale ruler = 500 nm; transmission electron microscopy characterization image of fusion membrane bubble, scale ruler = 2 μm.
[0031] Figure 4 This is a characterization diagram of the fusion membrane bubble of the present invention. The cell membrane and liposome are marked with membrane dyes DiO and DiI respectively. After repeated freeze-thaw fusion, they are excited with a laser of 460nm wavelength and the fluorescence emission spectrum within the wavelength range of 480-680nm is received.
[0032] Figure 5 Characterization diagram of the fusion membrane bubble of the present invention, confocal characterization of the fusion membrane bubble: bright field diagram of the fusion membrane bubble, scale = 5 μm; green fluorescence comes from the cell membrane labeled with DiO; red fluorescence comes from the liposome labeled with DiI; DiO and DiI dye fluorescence co-localization diagram.
[0033] Figure 6 This is a characterization diagram of the fusion membrane bubble protein of the present invention, and the bubble fluorescent antibody labeled flow characterization. The red curve represents the liposome bubble, and the blue curve represents the fusion membrane bubble labeled with the fluorescent antibody.
[0034] Figure 7 These are the SDS-PAGE characterization diagrams of the fusion membrane bubble protein of the present invention: 1) fusion membrane bubble, 2) fusion membrane, 3) cell membrane.
[0035] Figure 8 These are the protein characterization diagrams of the fusion membrane bubble of the present invention: 1) fusion membrane bubble, 2) cell membrane, 3) Western Blot characterization results of the total protein of HepG2 cells.
[0036] Fig. 9 These are confocal characterization images of the in vitro foam cell targeting of the present invention: 1) PBS group, scale bar = 10 μm; 2) DiO-labeled liposome bubbles L-MB; 3) DiO-labeled fusion membrane bubbles CL-MB.
[0037] Fig.10 The present invention is a flow chart of the method for preparing engineered fusion membrane bubbles. DETAILED DESCRIPTION
[0038] In order to make the purpose, technical solutions and advantages of the present invention more clear, the present invention is described in detail below with reference to the accompanying drawings and specific embodiments.
[0039] It should be emphasized that in the process of describing the present invention, various formulas and constraints are distinguished by consistent labels, but the use of different labels to mark the same formula and / or constraints is not excluded. The purpose of this setting is to more clearly illustrate the characteristics of the present invention.
[0040] The present invention provides a method for preparing an engineered fusion membrane bubble. The present invention uses bafilomycin A1 to stimulate hepatocytes cultured in vitro to express apolipoprotein A1, then freezes and thaws the cells and then extracts the cell membrane by differential centrifugation, then repeatedly freezes and thaws to promote the full fusion between the phospholipid bilayers to obtain a fusion membrane, and finally fills sulfur hexafluoride gas in the molecular rearrangement process of ultrasonic gas-liquid interface to form a fusion membrane bubble with uniform particle size and stable structure. The engineered fusion membrane bubble of the present invention includes an inert gas core and an engineered fusion membrane formed by the fusion of cell membrane and liposome coated on the outside of the gas core. The particle size of the fusion membrane bubble is 1.518±0.056μm, and the zeta potential is -18.94±9.07mV. The cell membrane and liposome of the fusion membrane bubble constitute a shell layer, and the shell layer contains CD47 and APOA1. The engineered fusion membrane bubble can be used in targeted ultrasound angiography of atherosclerotic plaques.
[0041] The method for preparing the engineered fusion membrane bubble of the present invention mainly comprises the following steps:
[0042] Step S1, extracting cell membrane using a cell membrane protein extraction kit after treating the cells with BAF;
[0043] Step S2, preparing liposomes by rotary evaporation;
[0044] Step S3, preparing a fusion membrane by repeatedly freezing and thawing the cell membrane extracted in step S1 and the liposome prepared in step S2 with liquid nitrogen;
[0045] Step S4: preparing fusion membrane bubbles from the fusion membrane prepared in step S3 using an ultrasound-assisted method.
[0046] Wherein, step S1 comprises the following steps:
[0047] Step S11, human liver cancer cells (HepG2) were cultured in a T75 cell culture flask containing RMPI-1640 medium containing 10% serum, washed 2-3 times with phosphate buffered saline (PBS), digested for 2-3 minutes with 4 mL of trypsin solution containing ethylenediaminetetraacetic acid (EDTA), and observed under a microscope until 80% of the cells fell off, and then 6 mL of RMPI-1640 medium containing 10% serum was added to terminate the digestion, and then the cells were transferred to a 15 mL centrifuge tube and centrifuged at 900 rpm for 3 minutes. After the supernatant was removed, the cells were resuspended with 1 mL of culture medium, 10 μL of the cell suspension was added to a cell counting plate, and then counted using a cell counter, and 4×10 cells were taken for each portion. 6 The cells were added into a 10 cm diameter dish and cultured for 24 hours;
[0048] Step S12, take out the culture medium in the dish of step S11, add PBS to wash 2-3 times, add RMPI-1640 incomplete culture medium containing BAF and incubate in an incubator for 6 hours, add RMPI-1640 incomplete culture medium to the control group, aspirate the culture medium after incubation, wash 2-3 times with PBS, add 4 mL PBS, use a cell scraper to scrape the cells and transfer them to a centrifuge tube;
[0049] Step S13, centrifuge the cells obtained in step S12 at 900 rpm for 3 minutes, remove the supernatant, then add cell membrane protein extraction reagent A to resuspend, mix well and freeze-thaw repeatedly in liquid nitrogen 2-3 times to lyse the cells, centrifuge the lysed cells at 700g and 4°C for 10 minutes to remove the cell nucleus precipitate, collect the supernatant and centrifuge at 14000g and 4°C for 30 minutes to obtain the precipitate, i.e., cell membrane fragments, which contain cell membranes and organelle membranes, resuspend the cell membrane fragments in PBS and sonicate in a water bath for 3-5 minutes to obtain a cell membrane suspension.
[0050] Wherein, step S2 comprises the following steps:
[0051] The phospholipids described in step S21 and step S2 are dissolved in chloroform and methanol in a volume ratio of 5:1 according to a mass ratio of 10:10:5:4 of dipalmitoylphosphatidylcholine (DPPC), distearate phosphatidylethanolamine-polyethylene glycol 2000 (DSPE-PEG2000), stearic acid and distearate phosphatidylglycerol (DPPG);
[0052] Step S22, rotary evaporate the liposome organic solution prepared in step S21 at 50°C and 100 rpm until a uniform thin film appears at the bottom of the round-bottom flask, remove the round-bottom flask, and vacuum dry it for 15 minutes. After drying, add 2 mL of PBS for every 29 mg of liposomes in the flask, and hydrate it under water bath ultrasound at 50°C, 100 w, 53 kHz for 5-10 minutes to obtain a liposome suspension.
[0053] Wherein, step S3 comprises the following steps:
[0054] Step S31, mixing the cell membrane suspension obtained in step S1 and the liposome suspension obtained in step S2 at a ratio of 1:0, 1:12.5, 1:25, 1:50, or 0:1 of the mass ratio of the cell membrane suspension protein to the liposome. Preferably, the mass ratio of the cell membrane suspension protein to the liposome is 1:50;
[0055] Step S32, freezing the mixed suspension obtained in step S31 in liquid nitrogen for 2 minutes, and then thawing it in a 37°C water bath under ultrasound, repeating the cycle 3-5 times to obtain a fusion membrane solution.
[0056] Wherein, step S4 comprises the following steps:
[0057] Step S41, taking 1 mL of the fusion membrane solution prepared in step S3 and placing it in a 10 mL vial and placing the vial on ice, opening the gas cylinder to pass sulfur hexafluoride into the vial, and placing an ultrasonic probe at the gas-liquid interface between sulfur hexafluoride and the fusion membrane solution, controlling the ultrasonic power to 300 W, the frequency to 25 kHz, the on time to 5 seconds, the off time to 5 seconds, and the total time to 1 minute, to obtain a fusion membrane bubble emulsion;
[0058] Step S42, adding 5 mL of the fusion membrane bubble emulsion obtained in step S42 into a 20 mL vial, freezing it in liquid nitrogen for 5-10 minutes, taking it out and freeze-drying it in a -40°C freeze dryer to obtain a freeze-dried powder;
[0059] Step S43, fill the freeze-dried powder bottle obtained in step S43 with 60 mg of sulfur hexafluoride gas, seal the bottle with a rubber stopper, clamp the aluminum cap, and store it in a 4°C refrigerator. When needed, add an equal volume of ultrapure water to reconstitute it, mix it in a water bath with ultrasound at room temperature and 53 kHz, and then inflate it through step S41.
[0060] The present invention is described in detail below with reference to the accompanying drawings and embodiments.
[0061] 1. Engineered cells, prepare cell membrane suspension. Human liver cancer cells HepG2 were cultured in a T75 cell culture flask containing RMPI 1640 medium with 10% serum, washed 2-3 times with PBS, and digested for 2-3 minutes with 4 mL of trypsin solution containing EDTA. After 80% of the cells were detached under microscope, 6 mL of RMPI 1640 medium containing 10% serum was added to terminate digestion and transferred to a 15 mL centrifuge tube for centrifugation at 900 rpm for 3 minutes. After the supernatant was removed, it was resuspended with 1 mL of culture medium, and 10 μL of cell suspension was added to the cell counting plate, and then counted using a cell counter. 4×106 cells were taken from each portion and added to a 10 cm diameter dish and cultured for 24 hours. The culture medium in the dish was removed, washed 2-3 times with PBS, and incomplete RMPI 1640 medium containing BAF was added and incubated in the incubator for 6 hours. The control group was added with incomplete RMPI 1640 medium. After the incubation was completed, the culture medium was removed, washed 2-3 times with PBS, and 4 mL PBS, use a cell scraper to scrape the cells and transfer them to a centrifuge tube, centrifuge the obtained cells at 900rpm for 3 minutes, remove the supernatant, add cell membrane protein extraction reagent A to resuspend, mix well, and freeze-thaw repeatedly 2-3 times to lyse the cells, centrifuge the lysed cells at 700g and 4℃ for 10 minutes to remove the cell nuclear precipitate, collect the supernatant and centrifuge at 14000g and 4℃ for 30 minutes to obtain the precipitate, i.e., cell membrane fragments, resuspend in water, and quantify the total cell membrane protein concentration using the BCA method, and store the cell membrane suspension in a -80℃ refrigerator for later use.
[0062] 2. Prepare liposome membrane solution. The phospholipids are dissolved in chloroform and methanol with a volume ratio of 5:2 according to the mass ratio of DPPC, DSPE-PEG2000, stearic acid and DPPG of 10:10:5:4, and the obtained liposome organic solution is rotary evaporated at 50°C and 100rpm until a uniform film appears at the bottom of the round-bottom flask, the round-bottom flask is removed, and vacuum dried for 15 minutes, and 2mL of 0.01M phosphate buffer solution is added to the dried flask for every 29mg of liposomes, and hydrated for 5-10 minutes under water bath ultrasonic conditions at 50°C, 100w, 53kHZ to obtain a liposome suspension.
[0063] 3. Preparation of fusion membrane solution. The mixed solution obtained in the above step was fully mixed by ultrasonication in a water bath at room temperature and 53 kHz, and then frozen in liquid nitrogen for 2 minutes. After being taken out, it was thawed in a water bath at room temperature and 53 kHz. After repeated freezing and thawing for 3 times, a fusion membrane solution was obtained.
[0064] 4. Prepare fusion membrane bubbles. Take 1 mL of the fusion membrane solution obtained in the above steps and place it in a 10 mL vial and place the vial on ice. Open the gas cylinder and pass sulfur hexafluoride into the vial. At the same time, place the ultrasonic probe at the gas-liquid interface between sulfur hexafluoride and the fusion membrane solution. Control the ultrasonic power to 300w, the frequency to 25kHZ, the on time to 5 seconds, the off time to 5 seconds, and the total time to 1 minute to obtain a fusion membrane bubble emulsion. Freeze the prepared bubble suspension in liquid nitrogen for 5-10 minutes, take it out and place it in a freeze dryer for freeze drying; after drying, fill the bottle with a sufficient amount of sulfur hexafluoride, cover the bottle cap, and store it at room temperature.
[0065] 5. Characterization of particle size, zeta potential and morphology of different components in the preparation process of fusion membrane bubbles. Take 20μL of cell membrane, fusion membrane and fusion membrane bubble respectively and add them to 2mL 10% (w / v) glucose solution, use ZetaPALS laser particle size analyzer to measure the particle size, and take 15μL of each component diluted in 1.5mL ultrapure water and insert the electrode to measure the Zeta potential. Take the prepared bubble suspension and dilute it 100 times, drop 10μL on a 200-mesh copper grid and let it stand to dry. Take cell membrane, liposome and fusion membrane and dilute them 100 times, drop 10μL on a 200-mesh copper grid, wait for it to dry, then use 1% phosphotungstic acid to negatively stain for 2min, use filter paper to absorb the staining solution, then drop a drop of pure water on the copper grid and absorb it with filter paper, repeat two or three times and let it stand to dry. Characterization was carried out using a Hitachi HT7700 transmission electron microscope at an accelerating voltage of 100kv.
[0066] 6. Protein characterization of fused membrane bubbles. APOA1 Elisa characterization: extract the cell membrane of BAF-treated cells and untreated HepG2 cells in the control group using cell membrane protein extraction reagent A. Fusion of a portion of the cell membrane extracted in the previous step with liposomes to obtain bubbles after ultrasonic aeration. Centrifuge at 50g for 1 minute, remove the supernatant and aerate again. Repeat the above operation 3 times and resuspend the remaining bubbles in PBS. Quantify the cell membrane, cell membrane and bubbles of BAF-treated cells using the BCA protein quantification kit and dilute to 1μg / μL. Take 100μL of BAF-treated cells containing cell membrane, cell membrane and bubbles to detect the content of APOA1 using the human APOA1 Elisa quantification kit. Flow cytometry characterization: take 100ul of fused membrane bubbles and liposome bubbles and incubate them with 10ul AF488-labeled Rat anti-APOA1 antibody for flow cytometry characterization. Collect the fluorescence signals of 3×105 bubbles and analyze the fluorescence intensity using FlowJ software. SDS-PAGE characterization, prepare SDS-PAGE electrophoresis fluid, dilute the total cell protein, cell membrane, and fusion membrane bubbles to a protein concentration of 1μg / ul, add 5x protein loading buffer containing DTT, boil in boiling water for 5min, and cool at room temperature for use. Add 10μL of pre-stained Marker to the precast gel, 20μL of total cell protein loading solution, cell membrane loading solution, and fusion membrane bubble loading solution. Set the electrophoresis instrument voltage to 100v, the time is 100 minutes, and the electrophoresis is terminated after the last colored band of the pre-stained Marker appears. Cut the target band with a cutting board and soak it in Coomassie Brilliant Blue Ultrafast Staining Solution for 3h. After staining, decolorize it in the decolorizing solution for one night and take a picture to obtain the target image. WB characterization, after taking out the precast gel, first add the PVDF membrane of appropriate size to methanol for activation for 1-2 minutes, and then lay the fiber pad, Whatman3MM filter paper, PVDF membrane, gel, Whatman3MM filter paper, and fiber pad into the transfer clamp in the transfer solution. During the laying process, the bubbles between each layer can be removed by rollers, and the membrane is transferred into the transfer tank using the Trans-Blot Turbo all-purpose protein transfer system. After the transfer, take out the PVDF membrane and mark it. Put the PVDF membrane into a box, add 5% skim milk powder and shake it on a shaker for 2h to block it. After blocking, take out the PVDF membrane and wash it 3 times with 1x TBST buffer slowly, each time for 10 minutes. Take the primary antibody of the membrane and incubate it slowly at room temperature for 2h, recover the primary antibody, add TBST buffer and repeat the membrane washing 3 times, incubate the secondary antibody at room temperature for 2h, repeat the membrane washing 3 times, and then take out the membrane and place it in TBST buffer. Prepare ECL chemiluminescence working solution. Place the membrane bound to the gel upward, add an appropriate amount of working solution, and use G:BOX chemiXR5 for imaging.
[0067] 7. Fusion membrane bubbles targeting foam cells in vitro. RAW264.7 cells cultured in a 10 cm round dish were blown down, centrifuged and resuspended in 1 mL of DMEM high glucose complete medium, 10 microliters were added to a cell counting plate for counting and the cell suspension concentration was adjusted to 100,000 / mL, 1 mL of cell suspension was added to the confocal dish for 24 hours, the medium was aspirated, PBS was washed 2-3 times, 1 mL of DMEM incomplete medium with a prepared Ox-LDL concentration of 20 μg / mL was added and incubated for 24 hours, PBS was washed 3 times, 400 μL of PBS, DiO-labeled liposome bubbles and DiO-labeled fusion membrane bubbles were added to the control group and the experimental group respectively, and incubated for 15-30 minutes, and PBS was washed twice and observed using a confocal microscope.
[0068] The above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention may be modified or replaced by equivalents without departing from the spirit and scope of the technical solution of the present invention.
Claims
1. A method for preparing an engineered fusion membrane bubble, characterized in that: The following steps are involved: Step S1, treating liver cancer HepG2 cells with BAF, i.e., bafilomycin A1, and then extracting cell membrane using a cell membrane protein extraction kit; Step S2, preparing liposomes by rotary evaporation; Step S3, preparing a fusion membrane by repeatedly freezing and thawing the cell membrane extracted in step S1 and the liposome prepared in step S2 with liquid nitrogen; as well as Step S4, preparing fusion membrane bubbles from the fusion membrane prepared in step S3 by using an ultrasound-assisted method; The liposome is composed of dipalmitoyl phosphatidylcholine, distearate phosphatidylethylamine alcohol-polyethylene glycol 2000, stearic acid and distearate phosphatidyl glycerol, wherein the mass ratio of dipalmitoyl phosphatidylcholine, distearate phosphatidylethylamine alcohol-polyethylene glycol 2000, stearic acid and distearate phosphatidyl glycerol is 10:10:5:4; the mass ratio of the cell membrane suspension protein obtained in step S1 to the liposome obtained in step S2 is 1:50; The step S4 comprises the following steps: Step S41, taking 1 mL of the fusion membrane solution prepared in step S3 and placing it in a 10 mL vial and placing the vial on ice, opening the gas cylinder to pass sulfur hexafluoride into the vial, and at the same time placing an ultrasonic probe at the gas-liquid interface between sulfur hexafluoride and the fusion membrane solution, controlling the ultrasonic power to 300 W, the frequency to 25 kHz, the on time to 5 seconds, the off time to 5 seconds, and the total time to 1 minute, to obtain a fusion membrane bubble emulsion; Step S42, adding 5 mL of the fusion membrane bubble emulsion obtained in step S42 into a 20 mL vial, freezing it in liquid nitrogen for 5-10 minutes, taking it out and freeze-drying it in a -40°C freeze dryer to obtain a freeze-dried powder; Step S43, fill the freeze-dried powder bottle obtained in step S43 with 60 mg of sulfur hexafluoride gas, seal the bottle with a rubber stopper, clamp the aluminum cap, and store it in a 4°C refrigerator. When needed, add an equal volume of ultrapure water to reconstitute it, mix it in a water bath with ultrasound at room temperature and 53 kHz, and then inflate it through step S41.
2. The method for preparing an engineered fusion membrane bubble according to claim 1, characterized in that: Step S1 includes the following steps: Step S11, the liver cancer HepG2 cells were cultured in a T75 cell culture flask containing RMPI-1640 medium containing 10% serum, washed 2-3 times with phosphate buffered saline (PBS), digested for 2-3 minutes with 4 mL of trypsin solution containing ethylenediaminetetraacetic acid, observed under a microscope until 80% of the cells fell off, and then 6 mL of RMPI-1640 medium containing 10% serum was added to terminate the digestion, and then the cells were transferred to a 15 mL centrifuge tube and centrifuged at 900 rpm for 3 minutes. After the supernatant was removed, the cells were resuspended with 1 mL of culture medium, 10 μL of the cell suspension was added to a cell counting plate, and then counted using a cell counter. 4×10 cells were taken for each portion. 6 The cells were added into a 10 cm diameter dish and cultured for 24 hours; Step S12, take out the culture medium in the dish of step S11, add PBS to wash 2-3 times, add RMPI-1640 incomplete culture medium containing BAF and incubate in an incubator for 6 hours, after the incubation is completed, remove the culture medium, wash 2-3 times with PBS, add 4 mL PBS, and use a cell scraper to scrape the cells and transfer them to a centrifuge tube; Step S13, centrifuge the cells obtained in step S12 at 900 rpm for 3 minutes, remove the supernatant, then add cell membrane protein extraction reagent A to resuspend, mix well and freeze-thaw repeatedly in liquid nitrogen 2-3 times to lyse the cells, centrifuge the lysed cells at 700g and 4°C for 10 minutes to remove the cell nucleus precipitate, collect the supernatant and centrifuge at 14000g and 4°C for 30 minutes to obtain the precipitate, i.e., cell membrane fragments, which contain cell membranes and organelle membranes, resuspend the cell membrane fragments in PBS and sonicate in a water bath for 3-5 minutes to obtain a cell membrane suspension.
3. The method for preparing the engineered fusion membrane bubble according to claim 2, characterized in that: Step S2 includes the following steps: Step S21: the liposomes described in step S2 are dissolved in chloroform and methanol in a volume ratio of 5:1 according to the mass ratio of dipalmitoyl phosphatidylcholine, distearate phosphatidylethylamine alcohol-polyethylene glycol 2000, stearic acid and distearate phosphatidylglycerol of 10:10:5:4; Step S22, rotary evaporate the liposome organic solution prepared in step S21 at 50°C and 100 rpm until a uniform thin film appears at the bottom of the round-bottom flask, remove the round-bottom flask, and vacuum dry it for 15 minutes. After drying, add 2 mL of PBS for every 29 mg of liposomes in the flask, and hydrate it under water bath ultrasound at 50°C, 100 w, 53 kHz for 5-10 minutes to obtain a liposome suspension.
4. The method for preparing the engineered fusion membrane bubble according to claim 3, characterized in that: Step S3 includes the following steps: Step S31, mixing the cell membrane suspension obtained in step S1 and the liposome suspension obtained in step S2 at a ratio of 1:50 between the mass of the cell membrane suspension protein and the mass of the liposome; Step S32, freezing the mixed suspension obtained in step S31 in liquid nitrogen for 2 minutes, and then thawing it in a 37°C water bath under ultrasound, repeating the cycle 3-5 times to obtain a fusion membrane solution.
5. An engineered fusion membrane bubble, characterized in that: Prepared according to the preparation method according to any one of claims 1 to 4.
Citation Information
Patent Citations
Exosome loading ABCA1 mRNA and construction method and application thereof
CN109234237A
Bionic lipid microbubble ultrasonic contrast agent constructed by cell membranes and preparation method of contrast agent
CN111330025A
Platelet membrane bionic ultrasonic microbubble as well as preparation method and application thereof
CN113769118A
